Peru Pharmaceuticals & Healthcare Report Q4 2014
Headline Expenditure Projections
Risk/Reward Rating: In BMI's RRRs for Q3 2014, Peru remains 10th out of the 18 markets surveyed in the Americas matrix. Peru's Reward and Risk scores are both viewed as being less favourable than the regional averages. A small market size and a deficient IP environment are some of the major drawbacks to the involvement of foreign companies in Peru. Nevertheless, Peru is still seen as being able to offer longer-term benefits to foreign investors, on account of the expected healthcare market development and economic growth.
- Pharmaceuticals: PEN4.38bn (USD1.62bn) in 2013 to PEN4.67bn (USD1.65bn) in 2014; +6.5% in local currency terms and +2.0% in US dollar terms. Local currency forecast decreased compared with Q214 projection due to less promising macroeconomic forecast.
- Healthcare: PEN27.74bn (USD10.26bn) in 2013 to PEN29.76bn (USD10.54bn) in 2014; +7.3% in local currency terms and +2.7% in US dollar terms. Local currency forecast decreased compared with Q214 projection due to less promising macroeconomic forecast.
Key Trends And Developments
The Peru Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.
- In March 2014, Peruvian doctors clashed with riot police during a 48-hour nationwide strike.
- In March 2014, Peru's ministry of Health published a list of 399 'rare or orphan' diseases and classified them into four groups.
- In February 2014, Peru's pharmaceutical industry registered production worth US$1.046mn to date, according to the National Association of Pharmaceutical Industries...
BMI's Peru Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Peruvian pharmaceutical and healthcare industry.
- Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Peru to test other views - a key input for successful budgeting and strategic business planning in the Peruvian pharmaceutical and healthcare market.
- Target business opportunities and risks in the Peruvian pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Peru.
- Assess the activities, strategy and market position of your competitors, partners and clients via our Company Profiles (inc. SWOTs, KPIs and latest activity) and Competitive Landscape Tables.
BMI Industry View & Industry SWOT
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI's forecast analysis, and taken together with BMI's political, economic and business environment SWOTS, it gives a complete overview of market climate.
Snapshot of key market characteristics, including total size of pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape.
Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as an analysis of the overall regulatory burden.
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.
BMI Industry Forecasts
Forecasts to end-2018 for all key industry indicators (see list below) supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:
Healthcare: Total healthcare expenditure (US$bn), healthcare expenditure (% of GDP), healthcare expenditure per capita (US$), hospital beds (per `000 population), doctors (per `000 population), birth and mortality rate (per `000 population)
Pharmaceutical market: Drug expenditure (US$bn), drug expenditure (% of GDP), drug expenditure per capita (US$)
Patented drug market: Prescription drug sales (US$bn), prescription sales (% of total sales), sales broken down by 14 therapeutic areas (cardiovascular, anti-infectives etc.)
Generic drug market: Generic product sales (US$bn), generic sales (% of total sales)
OTC drug market: OTC sales (US$bn), OTC sales (% of total sales), sales broken down by product types (analgesics, skin treatments, vitamins and minerals etc.)
Medical Devices: Medical device sales (US$bn), medical device sales (% of total healthcare market)
Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt.
The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.
Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI's industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.
Although per capita medicine spending in Peru is among the lowest in Latin America, pharmaceutical companies can generate rapid sales growth in the country due to the lack of a mandatory medicine pricing system in the country. More stringent quality control, a relatively weak domestic pharmaceutical industry, the ongoing liberalisation of bilateral trade agreements and the healthcare reform as well as Peru's investor-friendly business environment will further benefit foreign companies.
BMI Industry View
Pharmaceutical Market Forecast
Table: Pharmaceutical Sales, Historical Data And Forecasts (Peru 2010-2018)
Healthcare Market Forecast
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Peru 2010-2018)
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Peru 2010-2018)
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Peru 2010-2018)
Prescription Drug Market Forecast
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Peru 2010-2018)
Patented Drug Market Forecast
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Peru 2010-2018)
Generic Drug Market Forecast
Table: Generics Drug Market Indicators, Historical Data And Forecasts (Peru 2010-2018)
OTC Medicine Market Forecast
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Peru 2010-2018)
Pharmaceutical Trade Forecast
Table: Pharmaceutical Trade Data And Forecasts (Peru 2012-2018)
Table: Pharmaceutical Trade Data And Forecasts local currency (Peru 2012-2018)
Other Healthcare Data
Key Risks To BMI's Forecast Scenario
Table: Peru - Economic Activity
Industry Risk Reward Ratings
Americas Risk/Reward Ratings
Peru Risk/Reward Ratings
Industry Trends And Developments
Table: Selected Causes of Death by Sex, 2010
Table: MINSA's Decentralised Institutions & Institutes, 2011
Healthcare Sector Developments
Table: Infrastructure, 2004-2009
Table: Key Goals of Parsalud II In Nine Regions
Research and Development (R&D)
Recent Regulatory Developments
Intellectual Property Regime
Table: Peruvian Watchdog of Pharmaceutical Products (Observatorio Peruano de Productos Farmac-uticos, OPPF)
Pricing And Reimbursement Developments
Table: Price Components Of Two Imported Medicines In Both Private And Public Sectors
Table: Public Procurement of Pharmaceuticals by Provider, 2007-2009 (PENmn)
Table: Peruvian Pharmaceutical Companies That Acquired GMP Accreditation In 2006
Table: Members of ADIFAN, 2011
Recent Pharmaceutical Sector Developments
Merck & Co
Teva (Corporaci-n Medco)
Table: Peru's Population By Age Group, 1990-2020 ('000)
Table: Peru's Population By Age Group, 1990-2020 (% of total)
Table: Peru's Key Population Ratios, 1990-2020
Table: Peru's Rural/Urban Population, 1990-2020
Pharmaceutical Expenditure Forecast Model
Healthcare Expenditure Forecast Model
Notes On Methodology
Risk/Reward Ratings Methodology
Table: Pharmaceutical Risk/Reward Ratings Indicators
This report does not have a list of Companies Mentioned available
This report does not have a press release associated with it